PDF(Pubmed)
Abstract：
Nonalcoholic fatty liver disease (NAFLD) describes a spectrum of liver abnormalities, from benign steatosis to nonalcoholic steatohepatitis (NASH). Because of their antioxidant capabilities, CeNPs have sparked a lot of interest in biological applications. This review evaluated the effectiveness of CeNPs in NAFLD evolution through in vivo and in vitro studies. Databases such as MEDLINE, EMBASE, Scopus, and Web of Science were looked for studies published between 2012 and June 2023. Quality was evaluated using PRISMA guidelines. We looked at a total of nine primary studies in English carried out using healthy participants or HepG2 or LX2 cells. Quantitative data such as blood chemical markers, lipid peroxidation, and oxidative status were obtained from the studies. Our findings indicate that NPs are a possible option to make medications safer and more effective. In fact, CeNPs have been demonstrated to decrease total saturated fatty acids and foam cell production (steatosis), reactive oxygen species production and TNF-α (necrosis), and vacuolization in hepatic tissue when used to treat NAFLD. Thus, CeNP treatment may be considered promising for liver illnesses. However, limitations such as the variation in durations between studies and the utilization of diverse models to elucidate the etiology of NAFLD must be considered. Future studies must include standardized NAFLD models.
摘要：
非酒精性脂肪性肝病（NAFLD）描述了一系列肝脏异常，从良性脂肪变性到非酒精性脂肪性肝炎（NASH）。由于它们的抗氧化能力，CeNP在生物应用中引起了很多兴趣。这篇综述通过体内和体外研究评估了CeNPs在NAFLD进化中的有效性。MEDLINE等数据库，EMBASE,Scopus,和WebofScience寻找2012年至2023年6月之间发表的研究。使用PRISMA指南评估质量。我们研究了使用健康参与者或HepG2或LX2细胞进行的总共9项主要研究。定量数据，如血液化学标记，脂质过氧化，和氧化状态是从研究中获得的。我们的研究结果表明，NPs是使药物更安全，更有效的一种可能选择。事实上,CeNP已被证明可以减少总饱和脂肪酸和泡沫细胞产生（脂肪变性），活性氧的产生和TNF-α（坏死），用于治疗NAFLD时，肝组织空泡化。因此，CeNP治疗可能被认为是有前途的肝病。然而,必须考虑研究之间持续时间的差异以及利用不同模型阐明NAFLD病因等局限性.未来的研究必须包括标准化的NAFLD模型。
